Metformin Downregulates PD-L1 Expression in Esophageal Squamous Cell Carcinoma by Inhibiting IL-6 Signaling Pathway

Metformin Downregulates PD-L1 Expression in Esophageal Squamous Cell Carcinoma by Inhibiting IL-6 Signaling Pathway

PurposeTo characterize the mechanism by which metformin inhibits PD-L1 expression in esophageal squamous cell carcinoma (ESCC) and to evaluate the effect of metformin on the antitumor immune response.MethodsThe Cancer Genome Atlas (TCGA) database was used to analyze the correlations between IL-6 and...

Full description

Bibliographic Details
Main Authors:	Yao Lu, Dao Xin, Lulu Guan, Mengli Xu, Yalan Yang, Yu Chen, Yuanyuan Yang, Andrea Wang-Gillam, Li Wang, Shanggang Zong, Feng Wang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-11-01
Series:	Frontiers in Oncology
Subjects:	metformin PD-L1 anti-PD-1 antibody esophageal squamous cell carcinoma IL-6/JAK2/STAT3 signaling pathway
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2021.762523/full

Similar Items

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
by: Angel Garcia-Diaz, et al.
Published: (2017-05-01)

Research trends on anti-PD-1/PD-L1 immunotherapy for esophageal cancer: A bibliometric analysis
by: Yuanyuan Yang, et al.
Published: (2022-11-01)

The efficacy and safety of antibodies targeting PD-1 for treatment in advanced esophageal cancer: A systematic review and meta-analysis
by: Yao Lu, et al.
Published: (2021-06-01)

Dual Blockade of Lactate/GPR81 and PD-1/PD-L1 Pathways Enhances the Anti-Tumor Effects of Metformin
by: Shaomeng Chen, et al.
Published: (2021-09-01)

EGCG Inhibits Tumor Growth in Melanoma by Targeting JAK-STAT Signaling and Its Downstream PD-L1/PD-L2-PD1 Axis in Tumors and Enhancing Cytotoxic T-Cell Responses
by: Dinoop Ravindran Menon, et al.
Published: (2021-10-01)

An updated review of immunotherapy in esophageal cancer: PD-L1 footprint
by: Juan Yao, et al.
Published: (2024-05-01)

Formin protein DAAM1 positively regulates PD-L1 expression via mediating the JAK1/STAT1 axis in pancreatic cancer
by: Rui Xu, et al.
Published: (2025-01-01)

Differentiation status determines the effects of IFNγ on the expression of PD-L1 and immunomodulatory genes in melanoma
by: Teitur Sævarsson, et al.
Published: (2024-12-01)

PYCR1 promotes the malignant progression of lung cancer through the JAK-STAT3 signaling pathway via PRODH-dependent glutamine synthesize
by: Lihong Zhang, et al.
Published: (2023-06-01)

Pleiotropic Effects of Metformin on the Antitumor Efficiency of Immune Checkpoint Inhibitors
by: Wenhui Liu, et al.
Published: (2021-02-01)

HSF1 is involved in immunotherapeutic response through regulating APOJ/STAT3-mediated PD-L1 expression in hepatocellular carcinoma
by: Hongxia Cheng, et al.
Published: (2023-12-01)

Biomarkers for immunotherapy in esophageal cancer
by: Xuelian Wang, et al.
Published: (2023-05-01)

Impact of the combination of sintilimab and chemotherapy on the tumor and paratumor PD‐L1, IDO, TIM‐3, FOXP3+ and CD8 expressions in patients with advanced esophageal squamous cell carcinoma
by: Shifa Zhang, et al.
Published: (2022-12-01)

Cytochalasin H enhances sensitivity to gefitinib in non-small-cell lung cancer cells through inhibiting EGFR activation and PD-L1 expression
by: Guihong Zhang, et al.
Published: (2024-10-01)

Expression of PD-L1 and PD-1 in Chemoradiotherapy-Naïve Esophageal and Gastric Adenocarcinoma: Relationship With Mismatch Repair Status and Survival
by: Maria C. Svensson, et al.
Published: (2019-03-01)

JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer
by: Chunwan Lu, et al.
Published: (2017-03-01)

IGFBP3 induces PD-L1 expression to promote glioblastoma immune evasion
by: Leilei Zhao, et al.
Published: (2024-02-01)

Safety and Efficacy of Concurrent or Sequential Radiotherapy Plus (PD-1) Inhibitors in Oligometastatic Esophageal Cancer
by: Duan Y, et al.
Published: (2023-01-01)

Inhibition of triple-negative breast cancer growth via delphinidin-mediated suppression of the JAK2/STAT3/PD-L1 pathway
by: Xiaoping Yu, et al.
Published: (2024-12-01)

Chemoimmunotherapy for esophageal squamous cell carcinoma—Summary and discussion of recent clinical trials
by: Zhen Zhang, et al.
Published: (2023-06-01)

SPIB Knockdown Inhibits the Immune Escape of Ovarian Cancer Cells by Reducing PD-L1 (CD274) Expression and Inactivating the JAK/STAT Pathway
by: Wenfei Gu, et al.
Published: (2023-09-01)

PD-1 and PD-L1 expression predict regression and prognosis following neoadjuvant radiochemotherapy of oesophageal adenocarcinoma
by: Holger H. Göbel, et al.
Published: (2022-05-01)

PD‐1/PD‐L1 based immunochemotherapy versus chemotherapy alone for advanced esophageal squamous cell carcinoma: A meta‐analysis focus on PD‐L1 expression level
by: Zixian Jin, et al.
Published: (2023-07-01)

Low Expression of Programmed Death 1 (PD-1), PD-1 Ligand 1 (PD-L1), and Low CD8+ T Lymphocyte Infiltration Identify a Subgroup of Patients With Gastric and Esophageal Adenocarcinoma With Severe Prognosis
by: Silvio Däster, et al.
Published: (2020-04-01)

Nomogram Based on Monocyte-to-Lymphocyte Ratio to Predict Survival of Unresectable Esophageal Squamous Cell Carcinoma Who Receive First-Line PD-1/PD-L1 Inhibitors Combined with Chemotherapy
by: Xiaolu Ma, et al.
Published: (2022-11-01)

The Cell-Autonomous Pro-Metastatic Activities of PD-L1 in Breast Cancer Are Regulated by N-Linked Glycosylation-Dependent Activation of STAT3 and STAT1
by: Nofar Erlichman, et al.
Published: (2023-09-01)

Metformin enhances the anti-tumor effects mediated by attenuated Salmonella typhimurium
by: Hun Huang, et al.
Published: (2024-06-01)

Perioperative immunotherapy for esophageal squamous cell carcinoma
by: Dan D. Wei, et al.
Published: (2024-02-01)

Pathogenesis and biomarkers of natural killer T cell lymphoma (NKTL)
by: Nagavalli Somasundaram, et al.
Published: (2019-03-01)

Identification of potential immunomodulators from Pulsatilla decoction that act on therapeutic targets for ulcerative colitis based on pharmacological activity, absorbed ingredients, and in-silico molecular docking
by: Li-rong Deng, et al.
Published: (2022-11-01)

The covalent modification of STAT1 cysteines by sulforaphane promotes antitumor immunity via blocking IFN-γ-induced PD-L1 expression
by: Qing Shi, et al.
Published: (2025-04-01)

PD0166285 sensitizes esophageal squamous cell carcinoma to radiotherapy by dual inhibition of WEE1 and PKMYT1
by: Qingyi Zhang, et al.
Published: (2022-11-01)

PD-1 Inhibitors in the Advanced Esophageal Cancer
by: Ye Hong, et al.
Published: (2019-11-01)

Prognostic Significance of Serum PD-L1 Level in Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma Treated with Combination Cytotoxic Chemotherapy
by: Fu R, et al.
Published: (2021-06-01)

Targeting the Microenvironment in Esophageal Cancer
by: Lei Wang, et al.
Published: (2021-08-01)

Inhibition of ATM reverses EMT and decreases metastatic potential of cisplatin-resistant lung cancer cells through JAK/STAT3/PD-L1 pathway
by: Mingjing Shen, et al.
Published: (2019-04-01)

PD-1 inhibitors combined with paclitaxel and cisplatin in first-line treatment of esophageal squamous cell carcinoma (ESCC): a network meta-analysis
by: Jia Zhao, et al.
Published: (2023-12-01)

Upregulation of PD-1/PD-L1 and downregulation of immune signaling pathways lead to more severe visceral leishmaniasis in undernutrition mice
by: Jinlei He, et al.
Published: (2024-01-01)

A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy
by: Yuanyuan Wang, et al.
Published: (2021-05-01)

Anticancer Effects of 6-Gingerol through Downregulating Iron Transport and PD-L1 Expression in Non-Small Cell Lung Cancer Cells
by: Dong Young Kang, et al.
Published: (2023-11-01)